View ValuationManabi-aidLtd 将来の成長Future 基準チェック /06現在、 Manabi-aidLtdの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Consumer Services 収益成長12.1%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesNew Risk • Mar 18New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 6.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported April 2023 fiscal period end). High level of non-cash earnings (67% accrual ratio). Shareholders have been substantially diluted in the past year (52% increase in shares outstanding). Market cap is less than US$10m (JP¥1.28b market cap, or US$8.04m). Minor Risk Share price has been volatile over the past 3 months (6.5% average weekly change).お知らせ • Dec 27Manabi-aid Co.,Ltd. to Report Q3, 2026 Results on Mar 17, 2026Manabi-aid Co.,Ltd. announced that they will report Q3, 2026 results on Mar 17, 2026New Risk • Dec 19New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: JP¥1.55b (US$9.86m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported April 2023 fiscal period end). High level of non-cash earnings (67% accrual ratio). Shareholders have been substantially diluted in the past year (52% increase in shares outstanding). Market cap is less than US$10m (JP¥1.55b market cap, or US$9.86m). Minor Risk Share price has been volatile over the past 3 months (5.5% average weekly change).お知らせ • Sep 27Manabi-aid Co.,Ltd. to Report Q2, 2026 Results on Dec 15, 2025Manabi-aid Co.,Ltd. announced that they will report Q2, 2026 results on Dec 15, 2025お知らせ • Jul 29Manabi-aid Co.,Ltd. to Report Q1, 2026 Results on Sep 16, 2025Manabi-aid Co.,Ltd. announced that they will report Q1, 2026 results on Sep 16, 2025New Risk • Jun 21New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 52% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported April 2023 fiscal period end). Share price has been highly volatile over the past 3 months (13% average weekly change). High level of non-cash earnings (67% accrual ratio). Shareholders have been substantially diluted in the past year (52% increase in shares outstanding). Minor Risk Market cap is less than US$100m (JP¥2.15b market cap, or US$14.7m).お知らせ • Jun 16+ 1 more updateManabi-aid Co.,Ltd., Annual General Meeting, Jul 30, 2025Manabi-aid Co.,Ltd., Annual General Meeting, Jul 30, 2025.お知らせ • Apr 01Manabi-aid Co.,Ltd. to Report Fiscal Year 2025 Results on Jun 13, 2025Manabi-aid Co.,Ltd. announced that they will report fiscal year 2025 results on Jun 13, 2025お知らせ • Jan 28Manabi-aid Co.,Ltd. to Report Q3, 2025 Results on Mar 17, 2025Manabi-aid Co.,Ltd. announced that they will report Q3, 2025 results on Mar 17, 2025New Risk • Oct 30New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (12% average weekly change). High level of non-cash earnings (67% accrual ratio). Market cap is less than US$10m (JP¥1.31b market cap, or US$8.54m).Valuation Update With 7 Day Price Move • Oct 10Investor sentiment improves as stock rises 16%After last week's 16% share price gain to JP¥790, the stock trades at a trailing P/E ratio of 19x. Average trailing P/E is 16x in the Consumer Services industry in Japan.お知らせ • Sep 28Manabi-aid Co.,Ltd. to Report Q2, 2025 Results on Dec 13, 2024Manabi-aid Co.,Ltd. announced that they will report Q2, 2025 results on Dec 13, 2024New Risk • Aug 05New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: JP¥1.33b (US$9.36m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (15% average weekly change). High level of non-cash earnings (67% accrual ratio). Market cap is less than US$10m (JP¥1.33b market cap, or US$9.36m). Minor Risk Revenue is less than US$5m (JP¥501m revenue, or US$3.5m).Valuation Update With 7 Day Price Move • Jul 24Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to JP¥839, the stock trades at a trailing P/E ratio of 20.2x. Average trailing P/E is 17x in the Consumer Services industry in Japan.お知らせ • Jul 06Manabi-aid Co.,Ltd. to Report Q1, 2025 Results on Sep 13, 2024Manabi-aid Co.,Ltd. announced that they will report Q1, 2025 results on Sep 13, 2024Valuation Update With 7 Day Price Move • Jun 19Investor sentiment improves as stock rises 24%After last week's 24% share price gain to JP¥1,066, the stock trades at a trailing P/E ratio of 25.7x. Average trailing P/E is 16x in the Consumer Services industry in Japan.お知らせ • May 30Manabi-aid Co.,Ltd. has completed an IPO in the amount of ¥710.04 million.Manabi-aid Co.,Ltd. has completed an IPO in the amount of ¥710.04 million. Security Name: Common Shares Security Type: Common Stock Securities Offered: 180,000 Price\Range: ¥970 Discount Per Security: ¥77.6 Security Name: Common Shares Security Type: Common Stock Securities Offered: 552,000 Price\Range: ¥970 Discount Per Security: ¥77.6 Transaction Features: Sponsor Backed OfferingBoard Change • May 28No independent directorsThere are 3 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 3 new directors. 1 experienced director. No highly experienced directors. No independent directors (3 non-independent directors). Auditor Kazuhisa Hayashida is the most experienced director on the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Manabi-aidLtd は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測TSE:184A - アナリストの将来予測と過去の財務データ ( )JPY Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数4/30/2023501932024N/A4/30/2022290-60-60-57N/Aアナリストによる今後の成長予測収入対貯蓄率: 184Aの予測収益成長が 貯蓄率 ( 0.8% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: 184Aの収益がJP市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: 184Aの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: 184Aの収益がJP市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: 184Aの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 184Aの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YConsumer-services 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 08:41終値2026/05/22 00:00収益2023/04/30年間収益2023/04/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Manabi-aid Co.,Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
New Risk • Mar 18New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 6.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported April 2023 fiscal period end). High level of non-cash earnings (67% accrual ratio). Shareholders have been substantially diluted in the past year (52% increase in shares outstanding). Market cap is less than US$10m (JP¥1.28b market cap, or US$8.04m). Minor Risk Share price has been volatile over the past 3 months (6.5% average weekly change).
お知らせ • Dec 27Manabi-aid Co.,Ltd. to Report Q3, 2026 Results on Mar 17, 2026Manabi-aid Co.,Ltd. announced that they will report Q3, 2026 results on Mar 17, 2026
New Risk • Dec 19New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: JP¥1.55b (US$9.86m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported April 2023 fiscal period end). High level of non-cash earnings (67% accrual ratio). Shareholders have been substantially diluted in the past year (52% increase in shares outstanding). Market cap is less than US$10m (JP¥1.55b market cap, or US$9.86m). Minor Risk Share price has been volatile over the past 3 months (5.5% average weekly change).
お知らせ • Sep 27Manabi-aid Co.,Ltd. to Report Q2, 2026 Results on Dec 15, 2025Manabi-aid Co.,Ltd. announced that they will report Q2, 2026 results on Dec 15, 2025
お知らせ • Jul 29Manabi-aid Co.,Ltd. to Report Q1, 2026 Results on Sep 16, 2025Manabi-aid Co.,Ltd. announced that they will report Q1, 2026 results on Sep 16, 2025
New Risk • Jun 21New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 52% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported April 2023 fiscal period end). Share price has been highly volatile over the past 3 months (13% average weekly change). High level of non-cash earnings (67% accrual ratio). Shareholders have been substantially diluted in the past year (52% increase in shares outstanding). Minor Risk Market cap is less than US$100m (JP¥2.15b market cap, or US$14.7m).
お知らせ • Jun 16+ 1 more updateManabi-aid Co.,Ltd., Annual General Meeting, Jul 30, 2025Manabi-aid Co.,Ltd., Annual General Meeting, Jul 30, 2025.
お知らせ • Apr 01Manabi-aid Co.,Ltd. to Report Fiscal Year 2025 Results on Jun 13, 2025Manabi-aid Co.,Ltd. announced that they will report fiscal year 2025 results on Jun 13, 2025
お知らせ • Jan 28Manabi-aid Co.,Ltd. to Report Q3, 2025 Results on Mar 17, 2025Manabi-aid Co.,Ltd. announced that they will report Q3, 2025 results on Mar 17, 2025
New Risk • Oct 30New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (12% average weekly change). High level of non-cash earnings (67% accrual ratio). Market cap is less than US$10m (JP¥1.31b market cap, or US$8.54m).
Valuation Update With 7 Day Price Move • Oct 10Investor sentiment improves as stock rises 16%After last week's 16% share price gain to JP¥790, the stock trades at a trailing P/E ratio of 19x. Average trailing P/E is 16x in the Consumer Services industry in Japan.
お知らせ • Sep 28Manabi-aid Co.,Ltd. to Report Q2, 2025 Results on Dec 13, 2024Manabi-aid Co.,Ltd. announced that they will report Q2, 2025 results on Dec 13, 2024
New Risk • Aug 05New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: JP¥1.33b (US$9.36m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (15% average weekly change). High level of non-cash earnings (67% accrual ratio). Market cap is less than US$10m (JP¥1.33b market cap, or US$9.36m). Minor Risk Revenue is less than US$5m (JP¥501m revenue, or US$3.5m).
Valuation Update With 7 Day Price Move • Jul 24Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to JP¥839, the stock trades at a trailing P/E ratio of 20.2x. Average trailing P/E is 17x in the Consumer Services industry in Japan.
お知らせ • Jul 06Manabi-aid Co.,Ltd. to Report Q1, 2025 Results on Sep 13, 2024Manabi-aid Co.,Ltd. announced that they will report Q1, 2025 results on Sep 13, 2024
Valuation Update With 7 Day Price Move • Jun 19Investor sentiment improves as stock rises 24%After last week's 24% share price gain to JP¥1,066, the stock trades at a trailing P/E ratio of 25.7x. Average trailing P/E is 16x in the Consumer Services industry in Japan.
お知らせ • May 30Manabi-aid Co.,Ltd. has completed an IPO in the amount of ¥710.04 million.Manabi-aid Co.,Ltd. has completed an IPO in the amount of ¥710.04 million. Security Name: Common Shares Security Type: Common Stock Securities Offered: 180,000 Price\Range: ¥970 Discount Per Security: ¥77.6 Security Name: Common Shares Security Type: Common Stock Securities Offered: 552,000 Price\Range: ¥970 Discount Per Security: ¥77.6 Transaction Features: Sponsor Backed Offering
Board Change • May 28No independent directorsThere are 3 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 3 new directors. 1 experienced director. No highly experienced directors. No independent directors (3 non-independent directors). Auditor Kazuhisa Hayashida is the most experienced director on the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.